메뉴 건너뛰기




Volumn 84, Issue 16, 2015, Pages 1620-1621

Will CSF biomarkers guide future therapeutic decisions in multiple sclerosis?

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERNEXIN; MITOXANTRONE; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

EID: 84928139471     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001506     Document Type: Editorial
Times cited : (13)

References (11)
  • 1
    • 84914173724 scopus 로고    scopus 로고
    • No evidence of disease activity: Indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis
    • Nixon R, Bergvall N, Tomic D, Sfikas N, Cutter G, Giovannoni G. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis. Adv Ther 2014;31: 1134-1154.
    • (2014) Adv Ther , vol.31 , pp. 1134-1154
    • Nixon, R.1    Bergvall, N.2    Tomic, D.3    Sfikas, N.4    Cutter, G.5    Giovannoni, G.6
  • 3
    • 84860448559 scopus 로고    scopus 로고
    • Neurofilaments as biomarkers in multiple sclerosis
    • Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler 2012;18:552-556.
    • (2012) Mult Scler , vol.18 , pp. 552-556
    • Teunissen, C.E.1    Khalil, M.2
  • 4
    • 84884471946 scopus 로고    scopus 로고
    • A comparative study of CSF neurofilament light and heavy chain protein in MS
    • Kuhle J, Plattner K, Bestwick JP, et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler 2013;19:1597-1603.
    • (2013) Mult Scler , vol.19 , pp. 1597-1603
    • Kuhle, J.1    Plattner, K.2    Bestwick, J.P.3
  • 5
    • 0036145606 scopus 로고    scopus 로고
    • Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability
    • Semra YK, Seidi OA, Sharief MK. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol 2002;122:132-139.
    • (2002) J Neuroimmunol , vol.122 , pp. 132-139
    • Semra, Y.K.1    Seidi, O.A.2    Sharief, M.K.3
  • 7
    • 84928139473 scopus 로고    scopus 로고
    • Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
    • Kuhle J, Disanto G, Lorscheider J, et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 2015;84:1639-1643.
    • (2015) Neurology , vol.84 , pp. 1639-1643
    • Kuhle, J.1    Disanto, G.2    Lorscheider, J.3
  • 8
    • 77949904336 scopus 로고    scopus 로고
    • Neurofilament light as a prognostic marker in multiple sclerosis
    • Salzer J, Svenningsson A, Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010;16:287-292.
    • (2010) Mult Scler , vol.16 , pp. 287-292
    • Salzer, J.1    Svenningsson, A.2    Sundstrom, P.3
  • 9
    • 79551478161 scopus 로고    scopus 로고
    • Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
    • Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011;69:83-89.
    • (2011) Ann Neurol , vol.69 , pp. 83-89
    • Gunnarsson, M.1    Malmestrom, C.2    Axelsson, M.3
  • 10
    • 84902186393 scopus 로고    scopus 로고
    • Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial
    • Romme Christensen J, Ratzer R, Bornsen L, et al. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial. Neurology 2014;82: 1499-1507.
    • (2014) Neurology , vol.82 , pp. 1499-1507
    • Romme Christensen, J.1    Ratzer, R.2    Bornsen, L.3
  • 11
    • 84890808806 scopus 로고    scopus 로고
    • Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis
    • Axelsson M, Malmestrom C, Gunnarsson M, et al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler 2014;20:43-50.
    • (2014) Mult Scler , vol.20 , pp. 43-50
    • Axelsson, M.1    Malmestrom, C.2    Gunnarsson, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.